PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
4.96%
Revenue growth similar to 3088.T's 4.90%. Walter Schloss would see if both companies share industry tailwinds.
8.17%
Gross profit growth above 1.5x 3088.T's 3.83%. David Dodd would confirm if the company's business model is superior in terms of production costs or pricing.
24.49%
EBIT growth similar to 3088.T's 24.75%. Walter Schloss might infer both firms share similar operational efficiencies.
28.69%
Operating income growth above 1.5x 3088.T's 13.52%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
-17.71%
Negative net income growth while 3088.T stands at 10.44%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-17.71%
Negative EPS growth while 3088.T is at 10.43%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-17.71%
Negative diluted EPS growth while 3088.T is at 10.37%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
0.00%
Share change of 0.00% while 3088.T is at zero. Bruce Berkowitz would see if slight buybacks (or dilution) matter in the bigger picture.
0.00%
Diluted share change of 0.00% while 3088.T is zero. Bruce Berkowitz might see a minor difference that could widen over time.
-100.00%
Both companies cut dividends. Martin Whitman would look for a common factor, such as cyclical downturn or liquidity constraints.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
34.57%
10Y revenue/share CAGR at 75-90% of 3088.T's 41.97%. Bill Ackman would press for new markets or product lines to narrow the gap.
-15.64%
Negative 5Y CAGR while 3088.T stands at 23.47%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
32.43%
3Y revenue/share CAGR 1.25-1.5x 3088.T's 22.98%. Bruce Berkowitz might see better product or regional expansions than the competitor.
-100.00%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
71.27%
Below 50% of 3088.T's 160.15%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
-21.87%
Negative 5Y net income/share CAGR while 3088.T is 189.19%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
70.89%
Below 50% of 3088.T's 264.31%. Michael Burry suspects a steep short-term disadvantage in bottom-line expansion.
No Data
No Data available this quarter, please select a different quarter.
24.39%
Below 50% of 3088.T's 64.15%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
70.99%
3Y equity/share CAGR above 1.5x 3088.T's 27.44%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
-100.00%
Both reduced dividends long-term. Martin Whitman might check if sector-level headwinds forced universal cuts.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
4.55%
Our AR growth while 3088.T is cutting. John Neff questions if the competitor outperforms in collections or if we’re pushing credit to maintain sales.
0.14%
Inventory shrinking or stable vs. 3088.T's 3.10%. David Dodd confirms the company’s supply-chain is more efficient if sales are unaffected.
2.08%
Similar asset growth to 3088.T's 2.03%. Walter Schloss finds parallel expansions or investment rates.
4.03%
BV/share growth above 1.5x 3088.T's 2.44%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.
-30.60%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
No Data
No Data available this quarter, please select a different quarter.
94.28%
SG&A growth well above 3088.T's 29.70%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.